Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 13 Show results per page	View Search Criteria \| Help With Results

Last Modified: 8/20/2007 First Published: 6/23/2003


1.		Phase I/II Study of Oral and Intramucosal Ad5CMV-p53 Gene in Patients With Diffuse Premalignant Carcinoma of the Oral Cavity or Oral Pharynx

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Prevention				Completed				18 and over				NCI				MDA-ID-00193 NCI-6053, NCT00064103, 6053

Last Modified: 7/1/1999 First Published: 5/1/1998


2.		Phase II Randomized Study of Two Treatment Regimens of Recombinant Adenoviral p53 Gene (Ad5CMV-p53 gene) Administered by Intratumoral Injections in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck (Summary Last Modified 07/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				RP-T-201 SCCC-97050, NCI-V98-1393

Last Modified: 4/1/2000 First Published: 9/1/1998


3.		Phase II Study of Ad5CMV-p53 in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Summary Last Modified 04/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				AVENTIS-T-202 MCC-11653, RP-T-202, NCI-V98-1394, NCT00003257

Last Modified: 1/18/2008 First Published: 6/1/2001


4.		Phase II Study of Surgery and Ad5CMV-p53 Gene Followed By Cisplatin and Radiotherapy in Patients With Newly Diagnosed Resectable Stage III or IV Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Hypopharynx, or Larynx

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				SWOG-S0011 S0011, NCT00017173

Last Modified: 7/19/2004 First Published: 9/1/2002


5.		Phase II Study of Docetaxel, Doxorubicin, and Ad5CMV-p53 Gene Therapy (INGN 201) in Patients With Locally Advanced Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				INTROGEN-201-010 MDA-ID-00008, NCT00044993

Last Modified: 5/1/2000 First Published: 1/1/1998


6.		Phase I Study of Percutaneous Injections of Adenovirus P53 Construct (Adeno-P53) for Hepatocellular Carcinoma (Summary Last Modified 05/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				Over 18				NCI				PCI-96-035 NCI-T96-0059, NCT00003147, T96-0059

Last Modified: 12/1/2002 First Published: 2/1/1998


7.		Phase I Study of Adenovirus p53 in Patients With Locally Advanced or Metastatic Bladder Cancer (Summary Last Modified 06/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				NCI				MDA-DM-96172 NCI-T96-0073, NCT00003167, T96-0073

Last Modified: 6/1/2001 First Published: 9/1/1998


8.		Phase I Study of Intralesional Gene Therapy Plus Chemotherapy in Patients With Breast Cancer (Summary Last Modified 06/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				Over 18				NCI				FCCC-97009 NCI-T97-0042, NCT00004038, T97-0042

Last Modified: 6/1/2002 First Published: 9/1/1998


9.		Phase I Study of Intraperitoneal Adenoviral p53 Gene Therapy in Patients With Advanced Recurrent or Persistent Ovarian Cancer (Summary Last Modified 06/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				NCI				UTSMC-089733300 NCI-T97-0096, NCT00003450, T97-0096

Last Modified: 6/1/2002 First Published: 11/1/1998


10.		Phase I Study of Adenovirus p53 in Patients with Platinum- and Paclitaxel-Resistant Ovarian Epithelial Cancer (Summary Last Modified 06/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				NCI				MDA-ID-97228 NCI-T97-0111, NCT00003588, T97-0111

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute